Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Hum Immunol. 2011 Jun;72(6):463-9. doi: 10.1016/j.humimm.2011.03.001. Epub 2011 Mar 14.

Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin.

Author information

  • 1Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.


T cells are being increasingly recognized as a significant component of influenza-specific immune responses in humans. Although an inactivated- and a live-attenuated influenza vaccine are now licensed for use in humans, their comparative ability to elicit T-cell responses against influenza is not well understood. Using the rapidly evolving H3N2 hemagglutinin (HA) as an antigenic model, we compared immune responses elicited by the trivalent inactivated influenza vaccine (TIV) and the live-attenuated influenza vaccine (LAIV) in a cohort of healthy adults 18-49 years of age. TIV elicited higher geometrical mean antibody titers than LAIV, whereas, LAIV elicited superior T-cell responses. Importantly, LAIV elicited higher magnitude T-cell responses toward the rapidly drifting variant region of HA that is prone to escape from antibody responses. These results have important implications for the deployment of influenza vaccines in years of antigenic mismatch and shift.

Copyright © 2011 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk